TARS Insider Trading

Insider Ownership Percentage: 8.25%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,581,173.28

Tarsus Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Tarsus Pharmaceuticals Share Price & Price History

Current Price: $43.50
Price Change: Price Increase of +0.6 (1.40%)
As of 05/15/2025 05:00 PM ET

This chart shows the closing price history over time for TARS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$42.90Closing price on 05/14/25:

SEC Filings (Institutional Ownership Changes) for Tarsus Pharmaceuticals (NASDAQ:TARS)

90.01% of Tarsus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TARS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$69Mbought$34MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M$0$200MTotal InflowsTotal Outflows
Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More on Tarsus Pharmaceuticals

Today's Range

Now: $43.50
Low: $41.88
High: $43.95

50 Day Range

MA: $48.14
Low: $41.46
High: $52.36

52 Week Range

Now: $43.50
Low: $20.08
High: $57.28

Volume

750,017 shs

Average Volume

698,013 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Who are the company insiders with the largest holdings of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals' top insider shareholders include:
  1. Bobak R Azamian (CEO)
  2. Seshadri Neervannan (COO)
  3. Bryan Wahl (General Counsel)
  4. Aziz Mottiwala (Insider)
  5. Dianne C Whitfield (Insider)
  6. Elizabeth Yeu Lin (Director)
  7. Jose M Trevejo (Insider)
  8. Andrew D Goldberg (Director)
Learn More about top insider investors at Tarsus Pharmaceuticals.

Who are the major institutional investors of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals' top institutional shareholders include:
  1. Jennison Associates LLC — 6.50%
  2. Vanguard Group Inc. — 5.30%
  3. Lord Abbett & CO. LLC — 3.17%
  4. Assenagon Asset Management S.A. — 2.93%
  5. Invesco Ltd. — 1.97%
  6. Northern Trust Corp — 0.87%
Learn More about top institutional investors of Tarsus Pharmaceuticals stock.

Which institutional investors are selling Tarsus Pharmaceuticals stock?

Within the last quarter, TARS stock was sold by these institutional investors:
  1. Jefferies Financial Group Inc.
  2. Invesco Ltd.
  3. Aberdeen Group plc
  4. Atika Capital Management LLC
  5. Lisanti Capital Growth LLC
  6. Grant GrossMendelsohn LLC
  7. Essex Investment Management Co. LLC
  8. Federated Hermes Inc.
In the last year, company insiders that have sold Tarsus Pharmaceuticals company stock include:
  1. Bobak R Azamian (CEO)
  2. Seshadri Neervannan (COO)
  3. Bryan Wahl (General Counsel)
Learn More investors selling Tarsus Pharmaceuticals stock.

Which institutional investors are buying Tarsus Pharmaceuticals stock?

In the previous quarter, TARS stock was acquired by institutional investors including:
  1. Nuveen LLC
  2. Russell Investments Group Ltd.
  3. Vanguard Group Inc.
  4. Lord Abbett & CO. LLC
  5. Jump Financial LLC
  6. Victory Capital Management Inc.
  7. Universal Beteiligungs und Servicegesellschaft mbH
  8. Quantbot Technologies LP
Within the last year, these company insiders have bought Tarsus Pharmaceuticals stock:
  1. Bobak R Azamian (CEO)
  2. Seshadri Neervannan (COO)
Learn More investors buying Tarsus Pharmaceuticals stock.